Business Context and Reporting Period
Company: Modular Medical, Inc. (MODD)
Filing Type: Form 8-K (Current Report)
Date of Report: March 20, 2025
Event Date: March 20, 2025 (Agreement); March 25-26, 2025 (Closing)
Business Overview: The Company is a medical device developer focused on the MODD1 product. This filing reports the entry into material definitive agreements for a private placement of securities to raise capital for working capital, supply-chain optimization, and regulatory submissions.
Key Financial Metrics and Transaction Details
| Metric | Value |
|---|---|
| Private Placement Gross Proceeds | Approximately $12 million |
| Concurrent Direct Placement Proceeds | Approximately $0.5 million |
| Total Aggregate Gross Proceeds | Approximately $12.5 million |
| Units Sold (Private Placement) | 6,247,656 Units |
| Units Sold (Direct Placement) | 260,417 Units |
| Offering Price per Unit | $1.92 |
| Warrant Exercise Price | $1.12 per share |
| Placement Agent Fee | 7.25% of gross proceeds plus $50,000 expense reimbursement |
| Financial Advisor Fee | $100,000 (Titan Partners Group) |
Note: This filing does not provide revenue, profit, cash flow, or margin data for a specific reporting period. It details a capital raise event.
Material Changes and Transaction Structure
- Securities Issued: Each Unit consists of two shares of Common Stock and one Warrant to purchase one share of Common Stock.
- Insider Participation: Certain affiliates, officers, and directors purchased 374,478 Units in the Private Placement.
- Warrant Terms: Warrants are immediately exercisable, expire four years from issuance, and include a 4.99% (or 9.99% at election) beneficial ownership limitation.
- Placement Agent Warrants: Newbridge Securities Corporation received warrants to purchase 874,672 shares (7.0% of Common Stock sold) at an exercise price of $1.40 per share, exercisable after six months.
- Lock-Up Agreements: Officers and directors are restricted from selling securities for 60 days post-closing. The Company is restricted from Variable Rate Transactions for one year post-closing.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds:
- General corporate and working capital purposes.
- Supply-chain optimization and margin improvement for the MODD1 product.
- Preparation for broad commercial availability.
- Preparation for FDA submission of a tubeless version of the MODD1 product (targeted for Q3 2025).
- Ongoing work to obtain the CE mark for overseas markets.
Regulatory Filings: The Company agreed to file a registration statement with the SEC within 30 days of the closing date to cover the resale of the issued securities.
Investor Verification Checklist
- Net Proceeds: Verify the final net cash received after deducting the 7.25% placement fee, $50,000 expense reimbursement, and $100,000 financial advisor fee.
- Dilution Impact: Calculate the total dilution from the issuance of 12,775,726 shares of Common Stock (2 shares per unit) plus the potential issuance of warrants.
- Registration Timeline: Monitor the filing of the Registration Statement within the required 30-day window to ensure liquidity for investors.
- Regulatory Milestones: Track the progress of the tubeless MODD1 product submission to the FDA, targeted for Q3 2025.
- Warrant Exercise: Review the Black-Scholes cash payout provision in the event of fundamental transactions.